Regen BioPharma, Inc. is dedicated to advancing regenerative medicine solutions across the United States. The company's scientific endeavors involve identifying small molecules that modulate NR2F6, with the aim of either stimulating immune cells for cancer treatments or suppressing them for managing autoimmune conditions. Currently, its product pipeline and therapeutic approaches are in nascent developmental phases. Established in 2012, Regen BioPharma, Inc. operates from its headquarters in La Mesa, California.